J Lab Med Qual Assur 2020; 42(1): 10-25
Published online March 31, 2020
Copyright © Korean Association of External Quality Assessment Service.
Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to:Soo-Youn Lee
Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel +82-2-3410-1834 Fax +82-2-3410-2719 E-mail firstname.lastname@example.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
External quality assessment (EQA) trials of conventional newborn screening tests for phenylketonuria, galactosemia, congenital adrenal hyperplasia, maple syrup urine disease, homocystinuria, and congenital hypothyroidism, as well as extended newborn screening tests using tandem mass spectrometry, were performed twice in 2018 and 2019. A total of 44 dried blood spot specimens were analyzed in each trial in 14–16 laboratories. Median, mean, standard deviation, minimum and maximum values, and cut-off values were evaluated for each analyte in the newborn screening tests. The proportion of correct answers was 95%–100%. EQA trials for the analyses of methylmalonic acid, vanillylmandelic acid, catecholamines, metanephrines, organic acids, and amino acids were also performed using two or three specimens per trial. A well-designed EQA program and continuous education can help improve the performance of metabolite testing.
Keywords: External quality assessment, Newborn screening, Tandem mass spectrometry, Amino acid, Organic acid, Metabolite
|View Full Text||PubReader|
|Abstract||Print this Article|
|E-mail alert||Export to Citation|
|Article as PDF||Open Access|